Andrew Ostor

A/Prof

The Australian National University

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Associate Professor Andrew Ostor is a faculty member at The Australian National University, Australia. His research primarily focuses on inflammatory diseases, particularly in the context of advanced therapies for conditions such as psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. Recent publications highlight his work on treatment efficacy and patient outcomes in immunemediated inflammatory diseases.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (6)

Atul Deodhar

Professor of Medicine

Oregon Health & Science University

UNITED STATES

View details

graeme jones

professor of rheumatology

University of Tasmania

AUSTRALIA

View details

Jessica Walsh

Associate Professor

UNITED STATES

View details

Pablo Fernández Peñas

Professor

University of Sydney

AUSTRALIA

View details

Philip Helliwell

Professor of Clinical Rheumatology

University of Leeds

UNITED KINGDOM

View details

Douglas White

Honorary Clinical Lecturer

University of Auckland

NEW ZEALAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrew Ostor

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials

Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease

Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immune-mediated inflammatory diseases–an observational study

Correction: Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis (Rheumatology and Therapy, (2023), 10, 5, (1385-1398), 10.1007/s40744-023-00586-6)

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial

Time to flare in giant cell arteritis and polymyalgia rheumatica: analysis from a single-centre Australian practice

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis

Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis

Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients

Collaborators (6)

Atul Deodhar

graeme jones

Jessica Walsh

Pablo Fernández Peñas

Philip Helliwell

Douglas White

Make your next move.